Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 25, Issue 3, 2001, Pages 463-493

  Mahadik, Sahebarao P ^a,b   Evans, Denise ^b   Lal, Harbans ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antioxidant defense; Antioxidant supplements; Essential polyunsaturated fatty acids (EPUFAs); Mental disorders; Oxidative stress; Reactive oxygen species; Schizophrenia

Indexed keywords

ANTIOXIDANT;

ALCOHOL CONSUMPTION; BRAIN INJURY; CALORIC INTAKE; DIET SUPPLEMENTATION; HUMAN; LIFESTYLE; LIPID PEROXIDATION; NERVE CELL DIFFERENTIATION; NEUROTRANSMISSION; OXIDATIVE STRESS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 0035033906     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(00)00181-0     Document Type: Article

References (202)

1. Effects of ADP on PGE formation in blood platelets from patients with depression, mania and schizophrenia
2. Vitamin E treatment of tardive dyskinesia
3. Vitamin E treatment for tardive dyskinesia
4. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous conical development
5. Oxidants and antioxidants in development and differentiation
6. Neuroleptic syndromes associated with antipsychotic drug use
7. Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain and retina
8. Potential link between dietary intake of fatty acids and behavior: Pilot exploration of serum lipids in attention-deficit hyperactivity disorder
9. Absence of neurodegenerative and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia
10. Superoxide-dependent and ascorbate-dependent formation of hydroxyl radicals from hydrogen peroxide in the presence of iron
11. Premorbid adjustment as predictor of outcome in schizophrenia: Results of a prospective study
12. Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells
13. Neurotrophins: A family of proteins supporting the survival of neurons
14. Subcortical excitatory amino acid levels after acute and sub-acute administration of typical and atypical neuroleptics
15. Childhood schizophrenia: Clinical study of 100 schizophrenic children
16. The prostaglandins: A family of biologically active lipids
17. Phosphatidylinositol hydrolysis: A multifunctional transducting mechanism
18. Low nerve growth factor (NGF) plasma levels in schizophrenic patients: A pilot study
19. - with unsaturated fatty acids
20. Advancing neurodevelopmental origin of schizophrenia
21. Brain morphology and schizophrenia: A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures
22. Post-mortem evidence of structural brain changes in schizophrenia: Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder
23. Mechanisms of antioxidant action: Preventive and chain breaking antioxidants
24. Glutathione peroxidase and CT scan abnormalities in schizophrenia
25. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: Relation to psychosocial variables
26. Increased calcium-dependent phospholipase A2 activity in vitamin E, and selenium-deficient rat lung, liver and spleen cytosol is time-dependent and reversible
27. Free radicals and the developmental pathophysiology of schizophrenic burnout
28. Chronic treatment with prolixine causes oxidative stress in rat brain
29. Premorbid social functioning in schizophrenia and bipolar disorder: Similarities and differences
30. Docosahexaenoic acid status of preterm infants at birth and following feeding with human milk or formula 1-3
31. Interaction between glutaminergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease
32. Astrocytosis in the molecular layer of the dentate gyms: A study in Alzheimer's disease and schizophrenia
33. Staining intensity of brain iron in patients with schizophrenia
34. Schizophrenia - A brain disease? A critical review of structural and cerebral abnormalities in the disorder
35. The docosahexaenoic acid (DHA. 22:6n-3) contents of erythrocytes a marker for the DHA content of brain phospholipids?
36. Oxidative stress, glutamate, and neurodegenerative disorders
37. Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs
38. Fat consumption and schizophrenia
39. Lack of bimodal distribution of ventricular size in schizophrenia
40. Essential fatty acids modulate apomorphine activity at dopamine receptors in cat caudate slices
41. Prenatal growth markers in schizophrenia: A monozygotic co-twin control study
42. Ventricular enlargement in poor-outcome schizophrenia
43. Neurobiology of schizophrenia
44. Oxygen species in prostaglandin biosynthesis in vitro and in vivo
45. Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients
46. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia
47. Ventricular enlargement at the onset of psychosis is associated with diagnostic outcome
48. Brain morphology in first-episode schizophrenic-like psychotic patients: A quantitative magnetic resonance imaging study
49. Lipid peroxidation and outcome of schizophrenia after first-episode of psychosis
50. The lipid membrane hypothesis of schizophrenia: Implications for possible clinical breath tests
51. Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: A study of normal subjects from Italy, Finland and the USA
52. Postmortem studies of the hippocampal formation in schizophrenia
53. The platelet polyphosphoinositide system in schizophrenia: The effects of neuroleptic treatment
54. Cytotoxicity and genotoxicity of lipid peroxidation products
55. Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects
56. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?
57. Cortical pruning and the development of schizophrenia
58. Possible association of schizophrenia with a disturbance in prostaglandin metabolism: A physiological hypothesis
59. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia
60. Maternal smoking during pregnancy and psychiatric adjustment in late adolescence
61. The detection of schizophrenia in infancy
62. Neurobiological antecedents of schizophrenia in children: Evidence for an inherited congenital neurointegrative defect
63. Infants at risk for schizophrenia: Sequelae of a genetic neurointegrative defect
64. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis
65. Age-related losses of cognitive and motor skills in mice are associated with oxidative protein damage in the brain
66. The etiologic heterogeneity of schizophrenia: Review and perspective
67. Increased serum phospholipase A2 activity in schizophrenia: A replication study
68. Increased platelet phospholipase A2 activity in schizophrenia
69. Alcohol dependence and hospitalization in schizophrenia
70. Cerebrospinal fluid prostaglandin E in depression, mania and schizophrenia compared to normals
71. A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two diseases
72. Neurological soft signs in neuroleptic-naive and neuroleptic treated schizophrenic patients and normal comparison subjects
73. Reactive oxygen species and the central nervous system
74. Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection system
75. Eicosanoid pathways and psychiatric disorders
76. Schizophrenia as a prostaglandin deficiency disease
77. Is the main problem in free radical damage caused by radiation, oxygen, and other toxins the loss of membrane essential fatty acids rather than the accumulation of toxic materials?
78. The relationship between schizophrenia and essential fatty acids and eicosanoid metabolism
79. Schizophrenia as a membrane lipid disorder which is expressed throughout the body
80. Prostaglandins and schizophrenia: Further discussion of the evidence
81. The membrane hypothesis of schizophrenia
82. Fatty acid levels in brains of schizophrenics and normal controls
83. CNS signal transduction in the pathophysiology and pharmacology of affective disorders and schizophrenia
84. Role of gangliosides in behavioral and biochemical actions of alcohol: Cell membrane structure and function
85. Schizophrenia: Manifestations, incidence and course in different cultures
86. Prenatal developmental disturbances in the limbic allocortex in schizophrenics
87. Three-dimensional cortical morphometry of the planum temporale in childhood-onset schizophrenia
88. Cerebral ventricular enlargement in schizophreniform disorder does not progress: A seven year follow-up study
89. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs
90. Study of neuropathologic changes in the striatum following 4, 8, and 12 months of treatment with fluphenazine in rats
91. Neuronal apoptosis: Current understanding of molecular mechanisms and potential role in ischemic brain injury
92. Cerebral ventricular size and cognitive impairment in chronic schizophrenia
93. Accumulation of diacylglycerol in platelet phosphoinositides turnover in schizophrenia: A biological marker of good prognosis?
94. Prostaglandin E1 treatment of schizophrenia: A second trial
95. Elevated prostaglandin E2 levels in schizophrenia
96. Tardive dyskinesia: Prevalence and risk factors
97. No differences in phospholipase-A2 activity between acute psychiatric patients and controls
98. Ventricle to brain ratio in schizophrenia: A controlled follow-up study
99. Erythrocyte membrane phospholipids in psychotic patients
100. First episode studies of schizophrenia: Criteria and characterization
101. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited
102. Study of the process of lipid peroxidation in patients with endogenous psychoses using gas chromatography
103. Heterogeneity of the psychoses: Is there a neurodegenerative psychosis?
104. The effects of ischemia and recirculation, hypoxia and recovery on antioxidant factors and b-adrenoreceptor density: Is the damage in erythrocytes a reflection of brain damage caused by complete cerebral ischemia and by hypoxia?
105. The anthropometric assessment of dysmorphic features in schizophrenia as an index of its developmental origins
106. Brain abnormality in schizophrenia: A systematic and quantitative review of volumetric magnetic resonance imaging studies
107. Smoking and vulnerability for schizophrenia
108. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor
109. Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis. A pilot study
110. Qualitative assessment of brain morphology in acute and chronic schizophrenia
111. Cerebrospinal fluid prostaglandin levels in depressed and schizophrenic patients
112. Alpha-tocopherol in tardive dyskinesia
113. Smoking and schizophrenia
114. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia
115. Increased manganese-superoxide dismutase activity in post-mortem brain from neuroleptic-treated psychotic patients
116. Essential fatty acids in the treatment of schizophrenia
117. Antioxidants in the treatment of schizophrenia
118. Free radical pathology and the antioxidant defense in schizophrenia
119. Cultured skin fibroblasts as a model for investigating schizophrenia
120. Oxidative injury and potential use of antioxidants in schizophrenia
121. Haloperidol alters rat cholinergic system: Enzymatic and morphological analysis
122. Neuroprotective actions of Olanzapine in rat: Mechanism
123. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naive patients at the onset of psychosis
124. Mitogenic response to basic fibroblast growth factor (bFGF) of skin fibroblasts from first-episode psychotic, chronic schizophrenic and bipolar patients
125. Elevated plasma lipid peroxides at the onset of non-affective psychosis
126. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: Comparison with bipolar and normal controls
127. Abnormal growth and morphology of fibroblasts from schizophrenic patients
128. Decreased adhesiveness and altered cellular distribution of fibronectin in fibroblasts from schizophrenic patients
129. Cultural and socioeconomic differences in dietary intake of essential fatty acids and antioxidants: Effects on the outcome
130. Altered signal transduction in fibroblasts from first-episode schizophrenic patients
131. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls
132. Membrane peroxidation and the neuropathology of Schizophrenia
133. Neuroprotective actions of Olanzapine in rat: Cholinergic function
134. Aspects of oxidative metabolism in schizophrenia
135. Programmed cell death: Implications for neuropsychiatric disorders
136. Plasma prostaglandin E2 metabolite in twins with schizophrenic disorder
137. Schizophrenic symptoms and dietary intake of n-3 fatty acids
138. Safety of antioxidant vitamins
139. The Nithsdale Schizophrenia Surveys 16: Breast-feeding and schizophrenia: Preliminary results and hypothesis
140. The Nithsdale Schizophrenia Surveys XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects
141. Glutamate-induced apoptosis results in a loss of striatal neurons in Parkinson's rat
142. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: Smoking as a cause of oxidative damage
143. Developmental model of negative syndromes in schizophrenia
144. Impaired antioxidant defense at the onset of psychosis
145. Neurodevelopmental schizophrenia: The rediscovery of dementia praecox
146. Enzymes of oxyradical metabolism after haloperidol treatment of rat
147. Progression of cerebroventricular enlargement and the subtyping of schizophrenia
148. Neurodevelopmental pathogenesis of schizophrenia
149. Elevated PLA2 activity in schizophrenics and other psychiatric patients
150. The glucocorticoid cascade hypothesis in man: Prolonged stress may cause permanent brain damage
151. Lipid composition of the normal human brain: Gray matter, white matter, and myelin
152. Excitatory amino acids and neuropsychiatric disorders
153. Glutamate receptor dysfunction and schizophrenia
154. Childhood patterns predictive of adult schizophrenia: A 30-year follow-up study
155. Prenatal exposure to maternal stress and subsequent schizophrenia
156. Evidence of enhanced lipid peroxidation in cerebrospinal fluid of patients taking phenothiazines
157. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation
158. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients
159. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment
160. Double blind placebo controlled trial of n-3 polyunsaturated fatty acids as an adjunct to neuroleptics
161. Electrophysiological correlates of peroxide damage in guinea pig hippocampus in vitro
162. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics
163. Volatile organic compounds in the breath of patients with schizophrenia
164. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism
165. Deterioration of spatial and nonsocial reference working memory in aged rats: Protective effect of life-long caloric restriction
166. Postmortem studies in schizophrenia
167. Oxidants in cigarette smoke: Radicals hydrogen peroxide, peroxinitrate, and peroxinitrate
168. Neurological soft signs in schizophrenia and character disorders: Organicity in schizophrenia with premorbid associality and emotional unstable character disorders
169. Schizophrenia as a developmental disorder of the cerebral cortex
170. Peroxidation induced changes in synaptosomal transport of dopamine and gamma-aminobutyric acid
171. Enzymes of the antioxidant defense system in chronic schizophrenic patients
172. Free radical pathology in schizophrenia: A review
173. Comorbidity of mental disorders with alcohol and other drug abuse
174. Influence of lipid peroxidation on [3H]ketanserin binding to 5-HT2 prefrontal cortex receptors
175. Current status of antioxidant therapy
176. Free radicals in the genesis of Alzheimer's disease
177. Increased phospholipid breakdown in schizophrenia: Evidence for the involvement of a calcium-dependent phospholipase A2
178. Phospholipid and prostaglandin hypotheses of schizophrenia
179. Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain
180. Prostaglandins
181. Elevated lipid peroxidation and phospholipase A2: Possible mechanism of the lower cell membrane essential polyunsaturated fatty acids in schizophrenia
182. Regulation of gamma-aminobutyric acid/barbiturate receptor gated chloride ion flux in brain vesicles by phospholipase A2: Possible role of oxygen radicals
183. Abnormally high neuronal density in the schizophrenic cortex
184. Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia
185. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia
186. Vitamin E in the treatment of tardive dyskinesia; a double-blind placebo-controlled study
187. Oxidative stress in neurodegenerative diseases
188. Omega-3 fatty acids in health and disease, and in growth and development
189. Metabolism of oxygen derivatives in Down's Syndrome
190. Calcium-dependent phospholipase A2 and schizophrenia. Letter to the Editor
191. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging, and in response to food restriction in the mouse
192. 31P-MR spectroscopy study
193. MRI brain abnormalities in chronic schizophrenia: One process or more?
194. Early intervention of schizophrenia: Can the course of the illness be altered?
195. Red cell membrane dynamics in schizophrenia. II. Fatty acid composition
196. Increased turnover of platelet phosphatidylinositol in schizophrenia
197. Protein oxidation associated with aging is reduced by dietary restriction of protein or calories
198. Size, shape and orientation of neurons in the left and right hippocampus: Investigation of normal asymmetries and alterations in schizophrenia